Germany

The new CFO succeeds Henrik Bøggild, who left the company after three and a half years to pursue another professional opportunity.

The acquisition comes as Bayer seeks to reinforce its position in ophthalmology amid growing biosimilar competition facing Eylea, which it co-developed with Regeneron.

Photon Flash radiotherapy delivers radiation more than 100 times faster than conventional radiotherapy techniques, to reduce damage to surrounding healthy tissue while effectively targeting tumors.

The device collects saliva-free exhaled breath condensate from the distal lung while minimizing contamination from the mouth, upper airways, and environment, and it integrates into standard diagnostic workflows.

The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).

The company grew revenue by 10% to EUR 1.75 billion (USD1.91 billion) while substantially improving profitability and cash generation.

The Maisons-Alfort plant, which previously operated under Sanofi’s ownership, specializes in fill-finish manufacturing at commercial scale.

Results confirmed that Caas vFFR is a safe and effective alternative to conventional pressure wire-based physiology for guiding treatment decisions in patients with intermediate coronary artery stenosis.

The transaction, which remains subject to customary regulatory approvals, marks the beginning of what both firms describe as Syntegon’s next major growth phase.

Construction crews have already broken ground on the expansion project, which Axplora expects to complete by February 2027.